VESYNC(02148.HK)悉數行使超額配股權 涉及4215萬股
格隆匯 1 月 11日丨VESYNC(02148.HK)發佈公吿,配發結果公吿所述的超額配股權已由聯席全球協調人(為彼等本身及代表國際包銷商)於2021年1月8日悉數行使,涉及合共4215萬股股份,相當於超額配股權獲行使前全球發售初始可供認購的發售股份總數約15%。公司將按每股發售股份5.52港元,即全球發售每股發售股份的發售價配發及發行超額配股股份。
經扣除與行使超額配股權相關的包銷費用及佣金以及其他發售開支後,公司自配發及發行超額配股股份收取的額外所得款項淨額約2.257億港元,將由公司按比例用於招股章程所載用途。此外,與全球發售有關的穩定價格期於2021年1月10日(星期日()即遞交香港公開發售申請截止日期後第30日)結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.